144 related articles for article (PubMed ID: 18515856)
1. Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo.
Sami S; Höti N; Xu HM; Shen Z; Huang X
J Biochem; 2008 Sep; 144(3):357-62. PubMed ID: 18515856
[TBL] [Abstract][Full Text] [Related]
2. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
3. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R
Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572
[TBL] [Abstract][Full Text] [Related]
4. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
Gao D; Xia Q; Lv J; Zhang H
Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752
[TBL] [Abstract][Full Text] [Related]
5. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
Chen CL; Sung J; Cohen M; Chowdhury WH; Sachs MD; Li Y; Lakshmanan Y; Yung BY; Lupold SE; Rodriguez R
J Pharmacol Exp Ther; 2006 Nov; 319(2):533-42. PubMed ID: 16868035
[TBL] [Abstract][Full Text] [Related]
7. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
Eikel D; Lampen A; Nau H
Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
[TBL] [Abstract][Full Text] [Related]
8. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells.
Castro LM; Gallant M; Niles LP
J Neurochem; 2005 Dec; 95(5):1227-36. PubMed ID: 16313512
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells.
Fortunati N; Bertino S; Costantino L; Bosco O; Vercellinatto I; Catalano MG; Boccuzzi G
Cancer Lett; 2008 Feb; 259(2):156-64. PubMed ID: 18006146
[TBL] [Abstract][Full Text] [Related]
10. Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Jones J; Bentas W; Blaheta RA; Makarevic J; Hudak L; Wedel S; Probst M; Jonas D; Juengel E
Int J Mol Med; 2008 Sep; 22(3):293-9. PubMed ID: 18698487
[TBL] [Abstract][Full Text] [Related]
11. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
Höti N; Chowdhury W; Hsieh JT; Sachs MD; Lupold SE; Rodriguez R
Mol Ther; 2006 Dec; 14(6):768-78. PubMed ID: 16990052
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells.
Borutinskaite VV; Navakauskiene R; Magnusson KE
Ann N Y Acad Sci; 2006 Dec; 1091():346-55. PubMed ID: 17341627
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma.
Angelucci A; Muzi P; Cristiano L; Millimaggi D; Cimini A; Dolo V; Miano R; Vicentini C; Cerù MP; Bologna M
Prostate; 2008 May; 68(6):588-98. PubMed ID: 18288684
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
Dong XF; Song Q; Li LZ; Zhao CL; Wang LQ
Neuro Endocrinol Lett; 2007 Dec; 28(6):775-80. PubMed ID: 18063935
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo.
Michaelis M; Suhan T; Cinatl J; Driever PH; Cinatl J
Int J Oncol; 2004 Dec; 25(6):1795-9. PubMed ID: 15547719
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation.
Sinn DI; Kim SJ; Chu K; Jung KH; Lee ST; Song EC; Kim JM; Park DK; Kun Lee S; Kim M; Roh JK
Neurobiol Dis; 2007 May; 26(2):464-72. PubMed ID: 17398106
[TBL] [Abstract][Full Text] [Related]
18. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
Yang Q; Tian Y; Liu S; Zeine R; Chlenski A; Salwen HR; Henkin J; Cohn SL
Cancer Res; 2007 Feb; 67(4):1716-24. PubMed ID: 17308113
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid induces polarization, neuronal-like differentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression.
Benítez JA; Arregui L; Cabrera G; Segovia J
Neuroscience; 2008 Oct; 156(4):911-20. PubMed ID: 18771712
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
Travaglini L; Vian L; Billi M; Grignani F; Nervi C
Int J Biochem Cell Biol; 2009 Jan; 41(1):225-34. PubMed ID: 18789398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
